Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas Sells 1,096 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 1,096 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the transaction, the chief accounting officer now directly owns 48,138 shares of the company’s stock, valued at $1,464,839.34. The trade was a 2.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

James George Chopas also recently made the following trade(s):

• On Friday, January 17th, James George Chopas sold 715 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $21,421.40.
• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $22,472.10.

Apellis Pharmaceuticals Trading Up 1.2 %

Shares of APLS opened at $30.76 on Friday. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a 50 day simple moving average of $31.95 and a two-hundred day simple moving average of $33.25. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm has a market cap of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the prior year, the firm posted ($1.17) earnings per share. The business’s revenue was up 78.3% on a year-over-year basis. On average, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently made changes to their positions in APLS. Amalgamated Bank increased its stake in Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after acquiring an additional 359 shares during the last quarter. KBC Group NV increased its position in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares during the last quarter. Wolverine Asset Management LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at $27,000. Finally, True Wealth Design LLC bought a new position in Apellis Pharmaceuticals during the third quarter valued at $27,000. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on APLS shares. Scotiabank dropped their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 6th. Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price for the company. Needham & Company LLC decreased their price target on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Oppenheimer cut their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Mizuho decreased their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).